10% Owner GC Corp. Buys $16.5M in Artiva Biotherapeutics Stock

summarizeSummary

GC Corp., a 10% owner of Artiva Biotherapeutics, purchased $16.5 million worth of common stock in an open market transaction, significantly increasing its stake.

check_boxKey Events

• Significant Insider Purchase

  GC Corp. and GC Cell Corp., both 10% owners, acquired 1,432,291 shares of common stock for a total of $16,499,992.32 in open market transactions on May 11, 2026.

• High Conviction at Premium Price

  The shares were purchased at an average price of $11.52, which is above the current stock price of $7.61, signaling strong confidence from the institutional investor.

• Increased Stake

  This purchase significantly increases GC Corp.'s direct and indirect holdings, bringing their post-transaction total to 4,391,969 shares.

• Follows Recent Capital Raise and Clinical Data

  This substantial investment comes shortly after Artiva Biotherapeutics announced positive clinical data for its lead program, AlloNK, and completed a $300 million public offering earlier in May.

auto_awesomeAnalysis

This is a substantial open-market purchase by a major institutional investor (10% owner), representing nearly 9% of the company's market capitalization. The transaction price of $11.52 per share is notably above the current market price of $7.61, indicating strong conviction from the investor. This follows a recent $300 million public offering and another large institutional purchase, suggesting continued institutional confidence in the company's prospects, particularly after recent positive clinical data for its lead program, AlloNK.